176 related articles for article (PubMed ID: 37301933)
1. Analysis and modeling of cancer drug responses using cell cycle phase-specific rate effects.
Gross SM; Mohammadi F; Sanchez-Aguila C; Zhan PJ; Liby TA; Dane MA; Meyer AS; Heiser LM
Nat Commun; 2023 Jun; 14(1):3450. PubMed ID: 37301933
[TBL] [Abstract][Full Text] [Related]
2. Expression dynamics of periodic transcripts during cancer cell cycle progression and their correlation with anticancer drug sensitivity.
Li CX; Wang JS; Wang WN; Xu DK; Zhou YT; Sun FZ; Li YQ; Guo FZ; Ma JL; Zhang XY; Chang MJ; Xu BH; Ma F; Qian HL
Mil Med Res; 2022 Dec; 9(1):71. PubMed ID: 36529792
[TBL] [Abstract][Full Text] [Related]
3. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
4. Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells.
Subramaniam V; Ace O; Prud'homme GJ; Jothy S
Exp Mol Pathol; 2011 Feb; 90(1):116-22. PubMed ID: 21040720
[TBL] [Abstract][Full Text] [Related]
5. Integrating genomics and proteomics data to predict drug effects using binary linear programming.
Ji Z; Su J; Liu C; Wang H; Huang D; Zhou X
PLoS One; 2014; 9(7):e102798. PubMed ID: 25036040
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
7. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands.
Crowe DL; Chandraratna RA
Breast Cancer Res; 2004; 6(5):R546-55. PubMed ID: 15318936
[TBL] [Abstract][Full Text] [Related]
8. Targeting the cell cycle in breast cancer: towards the next phase.
Thu KL; Soria-Bretones I; Mak TW; Cescon DW
Cell Cycle; 2018; 17(15):1871-1885. PubMed ID: 30078354
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
10. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
Huang L; Pardee AB
Mol Med; 2000 Oct; 6(10):849-66. PubMed ID: 11126200
[TBL] [Abstract][Full Text] [Related]
11. BC-N102 suppress breast cancer tumorigenesis by interfering with cell cycle regulatory proteins and hormonal signaling, and induction of time-course arrest of cell cycle at G1/G0 phase.
Lawal B; Kuo YC; Wu ATH; Huang HS
Int J Biol Sci; 2021; 17(12):3224-3238. PubMed ID: 34421361
[TBL] [Abstract][Full Text] [Related]
12. Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer.
Gunasekaran VP; Nishi K; Sivakumar D; Sivaraman T; Mathan G
Eur J Pharm Sci; 2018 Apr; 116():2-14. PubMed ID: 28916481
[TBL] [Abstract][Full Text] [Related]
13. Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations.
Lindholm EM; Krohn M; Iadevaia S; Kristian A; Mills GB; Mælandsmo GM; Engebraaten O
Clin Cancer Res; 2014 Jan; 20(2):404-12. PubMed ID: 24192926
[TBL] [Abstract][Full Text] [Related]
14. Cell Line-Specific Network Models of ER
Gómez Tejeda Zañudo J; Mao P; Alcon C; Kowalski K; Johnson GN; Xu G; Baselga J; Scaltriti M; Letai A; Montero J; Albert R; Wagle N
Cancer Res; 2021 Sep; 81(17):4603-4617. PubMed ID: 34257082
[TBL] [Abstract][Full Text] [Related]
15. Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study.
Sterin M; Cohen JS; Mardor Y; Berman E; Ringel I
Cancer Res; 2001 Oct; 61(20):7536-43. PubMed ID: 11606391
[TBL] [Abstract][Full Text] [Related]
16. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative and antimetastatic characterization of an exo-heterocyclic androstane derivative against human breast cancer cell lines.
Kulmány ÁE; Frank É; Kovács D; Kirisits K; Krupitza G; Neuperger P; Alföldi R; Puskás LG; Szebeni GJ; Zupkó I
Biomed Pharmacother; 2021 Aug; 140():111728. PubMed ID: 34020244
[TBL] [Abstract][Full Text] [Related]
18. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis.
Iadevaia S; Lu Y; Morales FC; Mills GB; Ram PT
Cancer Res; 2010 Sep; 70(17):6704-14. PubMed ID: 20643779
[TBL] [Abstract][Full Text] [Related]
19. Corydalis yanhusuo W.T. Wang extract inhibits MCF-7 cell proliferation by inducing cell cycle G2/M arrest.
Xu Z; Chen X; Zhang Q; Chen L; Wang Y
Am J Chin Med; 2011; 39(3):579-86. PubMed ID: 21598423
[TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
Salvador MA; Wicinski J; Cabaud O; Toiron Y; Finetti P; Josselin E; Lelièvre H; Kraus-Berthier L; Depil S; Bertucci F; Collette Y; Birnbaum D; Charafe-Jauffret E; Ginestier C
Clin Cancer Res; 2013 Dec; 19(23):6520-31. PubMed ID: 24141629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
